The main objective of this trial is to investigate relative bioavailability of BI 456906 formulation B and BI 456906 formulation C vs. BI 456906 formulation A.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Formulation A
Formulation B
Formulation C
Humanpharmakologisches Zentrum Biberach
Biberach/Riß, Germany
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Time frame: Up to 22 days
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: Up to 22 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to 22 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.